Monoclonal antibodies (MAbs) of predefined specificity have been generated by utilizing a synthetic peptide reflecting amino acid positions 10-17 of the Hu-ras'"4 gene product as immunogen. These MAbs, designated RAP-1 through RAP-5 (RA, ras; P, peptide), have been shown to react with the ras gene product p2l. Since the Hu-ras reactive determinants (positions 10-17) have been predicted to be within the tertiary structure of the p21 molecule, it was not unexpected that denaturation of cell extracts or tissue sections with Formalin or glutaraldehyde enhanced binding of the RAP MAbs. When paraffin-embedded Formalin-fixed tissue sections and the avidin-biotin complex immunoperoxidase method were used, the RAP MAbs clearly defined enhanced ras p21 expression in the majority of human colon and mammary carcinomas. The majority of all abnormal ducts and lobules from fibroadenoma and fibrocystic disease patients were negative, as were all normal mammary and colonic epithelia examined.
The findings reported here form the basis for quantitative radioimmunoassays for a ras translational product and provide a means to evaluate ras p21 expression within individual cells of normal tissues and benign, "premalignant," and malignant lesions.
ras oncogenes were originally recognized as the transforming genes of two rat-derived viruses, the Harvey (Ha) and Kirsten (Ki) strains of murine sarcoma virus (1) . Molecular cloning studies have identified Ha-ras, Ki-ras, and subsequently N-ras, as members of a gene family present in a wide range of species, including humans (2) . At least two mechanisms have been identified by which ras activation can mediate transformation of NIH 3T3 mouse cells: (i) a point mutation in the ras gene resulting in an alteration of a single amino acid in the 21,000-dalton ras gene product, p21 (3) , or (ii) increased expression of p21 (1, 4, 5) . ras activation has been detected in certain human tumor cell lines and selected biopsy materials from a variety of cancers by the demonstration of the transforming potential of DNA from those specimens for NIH 3T3 cells; only a small percentage (usually less than 10-30%) of specimens tested from any given human tumor system, however, have proven positive for activated ras in this system (ref. 6 ; S. Aaronson, personal communication). One possible explanation for this is that the mechanism of ras activation in these tumors may involve the increased expression of a normal cellular ras gene and gene product [e.g., hormone activation of ras via a promoter sequence (7) ].
An alternative approach to determining whether correlations exist between enhanced ras gene expression (activation) and a particular neoplastic state would be the use of immunologic assays directed against p21. Radioimmunoassays (RIAs) would provide a quantitative determination of ras gene expression, while immunohistochemical studies would define ras gene expression in circumstances in which other methods are not suitable-i.e., the determination of ras gene expression in normal epithelium, hyperplastic lesions, and adjacent malignant tissues from the same patient. In light of the provocative findings on ras gene activation in selected colon carcinoma cell lines (6) and a human breast carcinosarcoma cell line (S. Aaronson, personal communication) and the recent finding of ras gene activation in carcinogen-induced rat mammary tumor models (8, 9) , we undertook the development of monoclonal antibodies (MAbs) to a human ras (Hu-ras) gene product. Since the DNA sequence of the entire human Ha-ras gene has been defined (3) and the studies of Lerner (10) have demonstrated an extremely efficient utilization of polyclonal antibodies prepared against synthetic peptides, the approach of preparing MAbs to a predefined set of ras amino acid sequences was undertaken.
MATERIALS AND METHODS Peptides. The following peptides (positions 10-17 of the Hu-ras gene product) were obtained from Peninsula Laboratories (San Carlos, CA): Hu-rasT24, Gly-Ala-Val-Gly-ValGly-Lys-Ser, and Hu-rasHa, Gly-Ala-Gly-Gly-Val-Gly-LysSer. Tyrosine was added to the amino terminus of each peptide for ease of iodination and lysine was added to the carboxyl terminus to facilitate solubilization of the peptides. Peptides were coupled to thyroglobulin as described (11) .
Hybridoma Methodology. BALB/c mice were immunized by intraperitoneal inoculation with 10 ,ug of the Hu-rasT24 peptide coupled to 120 ,ug of thyroglobulin on day 1 (in complete Freund's adjuvant) and day 7 (in incomplete Freund's adjuvant). At day 14, 1 ,ug of peptide coupled to 12 ,ug of thyroglobulin was administered intravenously. Spleens were removed at day 17 for cell fusion (12, 13) . All hybridoma cell lines were cloned twice. MAbs B1.1 [directed against carcinoembryonic antigen (14) ], UPC-10 [a purified mouse myeloma protein of the IgG2a isotype (15) ], and YA6 259 [a rat anti-rat ras, supplied by M. Furth (16)] have been described. Purified immunoglobulins were prepared as described (17) .
Immunoperoxidase Studies. The avidin-biotin complex immunoperoxidase assay was performed on 5-,m sections from Formalin-fixed paraffin-embedded tissues as described (18, 19) . In all cases an isotype-identical primary antibody (UPC-10) was used as a negative control. *To whom reprint requests should be addressed.
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Proc. Natl. Acad. Sci. USA 81 (1984) through RAP-5 (RA, ras; P, peptide). Each was determined to be the IgG2a isotype. Fig. 1 Lane b, p21 detected in a dimethylbenzanthracene-induced rat mammary tumor (8) by MAb RAP-5. One hundred micrograms of tumor extract was subjected to NaDodSO4/PAGE and transferred to nitrocellulose as described (20 Fig. 3 C and D) . RAP MAb dilution experiments demonstrate that most "positive" mammary carcinomas contain cells that score positive for cytoplasmic ras expression at MAb endpoint dilutions 32-fold to 320-fold higher than cells in the vast majority of benign lesions ( Table 1) . As seen in (Fig. 4) . It is interesting to note that the two fibroadenomas positive for ras gene expression (Fig. 4B, denoted a and b) were from two patients with multiple fibroadenomas (see Discussion). The 1 of 11 fibrocystic disease lesions examined (Fig. 4B, patient c) of all abnormal ducts and lobules from fibroadenoma patients ( Fig. 3E ) and fibrocystic disease patients (Fig. 3F) were negative. Normal lobules and ducts from breasts of fibroadenoma patients and fibrocystic disease were also routinely negative for ras gene expression.
In mammary carcinomas was even more unexpected in light of the fact that DNA transfection experiments looking for activated ras expression in human breast cancers have been thus far unsuccessful. Two possible explanations for these observations could be that (i) the NIH 3T3 foci indicator system is not efficient for this particular ras gene, or (ii) the mechanism of ras activation in many colon and mammary carcinomas involves the enhanced expression of a normal c-ras gene, perhaps at times, via a hormonally controlled promoter sequence; DNA transfection experiments would not necessarily score positive for this type of mechanism. It is interesting to note that the only two benign breast lesions that scored with percentages of tumor cells positive similar to those of the mammary carcinomas were from patients (Fig.  4B , patients a and b) with multiple fibroadenomas (a total of 7 tumors removed from the two patients prior to 24 years of age). Hormonal factors have been implicated in the development of these lesions and for severe chronic mastitis (Fig.   4B , patient c) (24) .
The studies reported here demonstrate that MAbs prepared against a set of predefined amino acid sequences, believed to be internally located in a molecule and thus not efficiently exposed for antibody binding in the native conformation, can be rendered available by simply altering the tertiary structure of the molecule with a substance such as Formalin (Fig. 2) . Fortunately, Formalin-fixed tissue sections have several advantages over frozen sections: finer histologic detail, ease of processing, and availability. Conversely, we have been unable to detect ras p21 with the YA6 259 antibody (prepared against native p21) in Formalin-fixed tissues.
The RAP MAbs do appear to react differentially to the Hu-rasT24 vs. the normal Hu-rasHa peptide. The solid-phase RIAs and solid-phase immunohistochemical assays reported here, however, are well suited for quantitative assessments. Qualitative evaluations will require liquid competition RIAs, using the RAP MAbs vs. the Hu-ras synthetic peptides, which can record differences in slopes with different competitors; these assays may thus detect the one amino acid change out of the six to eight needed for effective antigenantibody union. The detection of ras p21 in solid-phase RIAs and N-ras). Thus, the immunoassays employed here should be termed "group specific" in that they recognize translational products from members of a group of related genes within a given species. Clearly, "type-specific" immunoassays, employing antibodies directed against peptides reflecting variable regions of the ras gene, will eventually be utilized to determine which of the Hu-ras genes is being expressed in a given cell.
The studies reported here demonstrate heterogeneity of ras gene expression among cells in a given colon or mammary carcinoma. Thus, if ras activation has anything to do with transformation of human colon or mammary epithelium, continuous expression in all tumor cells is not necessary for maintenance of the transformed phenotype. Several possible explanations for this phenomenon are as follows: (0) a cell cycle dependency for ras gene expression, as is seen for other tumor antigens (25, 26) ; (ii) the milieu of the individual cell (i.e., its exposure to endocrine, paracrine, or autocrine factors); or (iii) ras activation was required at the time of transformation, but subsequently, during the evolution of the tumor, other mechanisms of immortality have come into play. This may particularly be true in the case of colon or mammary carcinomas, in which the interval between the transformation event and tumor detection is believed to be from 5 to greater than 10 years. The quantitative ras p21 RIAs developed, as well as the use of Formalin-fixed tissue specimens for identification of particular cell types expressing ras p21, now make possible the direct evaluation (both retrospective and prospective) of clinical material in an attempt to define the precise role, if any, of ras gene translational products in the processes of carcinoma initiation, promotion, and progression.
